MediWound Receives Additional Funding from DoD
MediWound has received an extra $6.7 million from the DoD to further develop NexoBrid as a non-surgical field care solution for the US military
On Dec. 28, 2023, MediWound, an Israel-based biopharmaceutical company, shared that they have received an additional $6.7 million from the US Department of Defense. This funding will support the development of NexoBrid, a non-surgical solution for field-care burn treatment for the US Army. The grant was awarded through the Medical Technology Enterprise Consortium, a biomedical technology consortium focused on developing medical solutions for US military personnel.
The increased funding has boosted MediWound's R&D budget to $14.4 million. This will enable the company to make significant progress in the development and production of a new formulation of NexoBrid that remains stable at different temperatures. According to a company press release, NexoBrid is being positioned as the leading non-surgical solution for treating severe burn injuries in pre-hospital settings.
NexoBrid is a specialized product that utilizes a unique blend of enzymes to effectively remove eschar in patients with deep partial and full-thickness thermal burns. Topical administration is used. The product has received approval in the United States, European Union, and other international markets.
Vericel, a US-based company specializing in sports medicine and severe burn care, has secured an exclusive license for the commercial and development rights to NexoBrid in North America under a potentially lucrative agreement worth up to $150 million. MediWound maintains commercial rights in all territories outside of North America.
"We are thrilled to strengthen our partnership with the US Department of Defense. "The additional funding will help us improve our CMC activities, speed up preclinical development, and set up a GMP-compliant aseptic production line for the temperature-stable formulation of NexoBrid," stated Ofer Gonen, CEO of MediWound, in the press release. "This new award highlights our dedication to making NexoBrid accessible for military applications and its potential to revolutionize the initial treatment of severe burns."
Source: MediWound
